HistoSonics Receives Approval To Begin European #HOPE4LIVER Clinical Study
Company Now Cleared to Use Its Novel Sonic Beam Therapy in Dual U.S. and European Studies
News provided by
Share this article
Share this article
MINNEAPOLIS, Jan. 11, 2021 /PRNewswire/ HistoSonics, developer of a non-invasive platform and novel sonic beam therapy, announced today that it has received approval to initiate the company s second European clinical trial of its new platform technology, which is designed to use the science of histotripsy to mechanically destroy targeted liver tumors, from outside of the body. The study, similar to HistoSonics recent FDA approved #HOPE4LIVER U.S. Study, is a multi-center, open label, single arm trial to evaluate the safety and efficacy in destroying liver tumors and will build upon the company s first-in-man THERESA Study recently conducted in Barcelona, Spain. The company expects to begin enrolling patients in early 2021.